Analytical Data
-
Gene name
Coagulation factor VII/F7
- Application
-
Alternative Names
FVII; SPCA; proconvertin; Cothromboplastin; Serum Prothrombin Conversation Accelerator; Stable Factor; Eptacog alfa
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8K3U6
-
Expression Region
Ile194~Leu446
-
Molecular Weight
61kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation factor VII (F7) is a crucial protein in the blood coagulation cascade, playing a key role in the initiation of clot formation. Deficiencies in F7 can lead to bleeding disorders, necessitating the development of therapeutic interventions. The advent of recombinant DNA technology has led to the production of recombinant coagulation factors, including F7, which can provide new treatment options for affected individuals. Research into recombinant factor VII products has gained momentum due to the limitations of traditional treatments, such as plasma-derived products, which may pose risks of viral transmission and allergic reactions. Clinical studies have demonstrated the effectiveness of recombinant F7 in managing bleeding episodes and preventing complications during surgical procedures in patients with hemophilia and F7 deficiency. Furthermore, the use of recombinant proteins allows for higher purity and more consistent dosing, addressing many challenges associated with existing therapies. As our understanding of the coagulation cascade and genetic factors influencing bleeding diatheses evolves, recombinant factor VII continues to be investigated for its potential applications, including in patients with other coagulopathies and trauma-induced coagulopathy. Overall, ongoing research into the safety, efficacy, and novel applications of recombinant F7 aims to enhance patient outcomes and expand therapeutic options in the field of hematology.
